Enteris BioPharma to attend 2021 Drug Distribution Partnership Opportunities (PODD) conference

Posted: October 26, 2021 at 8:30 a.m. EDT|Update: 2 hours ago

BOONTON, New JerseyOct. 26, 2021 / PRNewswire / –Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), has announced today that the company will attend the 2021 Drug Delivery Partnership Opportunities (PODD) conference that will be held virtually October 28-29, 2021.

During the conference, members of the Enteris leadership team will host virtual meetings with pharmaceutical executives to explore opportunities involving Peptelligence® and ProPerma®, the company’s new formulation technologies that enable oral delivery of BCS Class III and IV compounds including peptides, peptidomimetics, small molecules, as well as recent contract development and manufacturing (CDMO) operations launched by the company and its expanded manufacturing facility. Enteris continues to advance internal and external programs that rely on Peptelligence and ProPerma, some of which are in advanced clinical development.

Rajiv khosla, Ph.D., CEO of Enteris, said: “We look forward to participating in PODD 2021 and the opportunity it offers us to interact with other innovators in drug delivery. The ability to enable peptides and small molecules to be delivered orally continues to gain the attention of the pharmaceutical industry, as highlighted by one of the key topics of this year’s conference: Advances oral administration of biological products. injectable to an oral tablet. “

About Enteris BioPharma
Enteris BioPharma, Inc. is a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) providing integrated contract development and manufacturing (CDMO) services, including innovative formulation solutions using its proprietary drug delivery technologies. drugs, Peptelligence® and ProPerma®. The technologies have been the subject of numerous feasibility studies and active development programs, many of which are in clinical development. In addition, Enteris BioPharma is developing an innovative internal pipeline of drug products that address significant unmet clinical needs for which there are no satisfactory treatment options. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit www.EnterisBioPharma.com.

Show original content:

SOURCE Enteris BioPharma, Inc.

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.

Previous 6 petroleum resources to stay on top of the evolution of energy markets
Next Note on changes to the CIRP and the liquidation process